LUZVIMINDA DORSETT: Open Payments
NPI 1508902008 · LONG BRANCH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$712 in 50 payments from 11 companies in 2025. Trend: 2023 $342 · 2024 $649 · 2025 $712
Food & beverage: $712
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 33 | $291 |
| Incyte Corporation | 2 | $140 |
| Janssen Biotech, Inc. | 3 | $52 |
| Merck Sharp & Dohme LLC | 3 | $48 |
| Cumberland Pharmaceuticals, Inc. | 1 | $38 |
| Agios Pharmaceuticals, Inc. | 2 | $35 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Eisai Inc. | 1 | $20 |
| ABBVIE INC. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
Products named: KISQALI, Jakafi, KEYTRUDA, SANCUSO, PYRUKYND, RYBREVANT, Lenvima, ELAHERE.
Industry payments across NJ — which companies pay providers there.
